Active substance
SOFOSBUVIR/VELPATASVIR
Therapeutical formulation
TABLETTEN EN CAPSULES

€ 321.16 € 8,992.50 excluding delivery costs.

This drug is fully reimbursed by your health insurance company.

Own risk

€ 321.16 € 8,992.50

This is the amount charged to your deductible per piece per package.

Strength
200/50MG
Supplier
GILEAD SCIENCES NETHERLANDS BV
Available outside pharmacies
No
Remarks
  • This medicine is available by prescription only.
EU number
EU/1/16/1116/002